Sponsored by
This is the problem with the current clinical trial system. These vaccines seem to work in a small % of patients, perhaps 30%. So when you have a trial report that the median overall survival and median progression feee survival did not change, they wrongly conclude the trial was a failure. I say wrongly because the median does not move if you cure 30% of the patients, only if you help over 50%. They should be looking at the 2,3,5 year survival rates. And they should be looking at the differences between the responders and non responders.